Drug Profile
HSPPC-56-I
Latest Information Update: 24 Jan 2003
Price :
$50
*
At a glance
- Originator Antigenics
- Class
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections; Mycoses; Parasitic infections; Viral infections
Most Recent Events
- 24 Jan 2003 No development reported - Preclinical for Bacterial infections in USA (unspecified route)
- 24 Jan 2003 No development reported - Preclinical for Mycoses in USA (unspecified route)
- 24 Jan 2003 No development reported - Preclinical for Parasitic infections in USA (unspecified route)